Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Oramed Pharmaceuticals (ORMP) Assets Average (2016 - 2026)

Oramed Pharmaceuticals filings provide 15 years of Assets Average readings, the most recent being $225.7 million for Q4 2025.

  • Quarterly Assets Average rose 40.89% to $225.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $225.7 million through Dec 2025, up 40.89% year-over-year, with the annual reading at $193.1 million for FY2025, 2.74% up from the prior year.
  • Assets Average hit $225.7 million in Q4 2025 for Oramed Pharmaceuticals, up from $191.1 million in the prior quarter.
  • Across five years, Assets Average topped out at $225.7 million in Q4 2023 and bottomed at $51.3 million in Q1 2021.
  • Average Assets Average over 5 years is $162.7 million, with a median of $163.2 million recorded in 2022.
  • The largest annual shift saw Assets Average skyrocketed 262.66% in 2021 before it decreased 29.04% in 2024.
  • Oramed Pharmaceuticals' Assets Average stood at $155.2 million in 2021, then grew by 5.03% to $163.0 million in 2022, then surged by 38.45% to $225.7 million in 2023, then decreased by 29.04% to $160.2 million in 2024, then soared by 40.89% to $225.7 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Assets Average are $225.7 million (Q4 2025), $191.1 million (Q3 2025), and $154.6 million (Q2 2025).